HI
QNCX icon

Harbour Investments’s Quince Therapeutics QNCX Stock Holding History

Harbour Investments’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$163 – 3992
2025
Q3 		$163 Hold
1
– – ﹤0.01% 3607
2025
Q2 		$165 Buy
+1
New +$229 ﹤0.01% 3486

Other funds holding QNCX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
SCM
Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Harbour Investments's QNCX Position: Q4 2025 in Review

Harbour Investments sold out of Quince Therapeutics (QNCX) in Q4 2025, closing a stake of 1 share — an estimated $163 sold.

Harbour Investments first reported a position in QNCX in Q2 2025 and held it in 2 quarters. The position peaked at $165 in Q2 2025. 62 funds tracked by Wall St. Rank hold QNCX as of Q4 2025.

  • Harbour Investments reported no remaining Quince Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Harbour Investments sold 1 Quince Therapeutics share in Q4 2025, an estimated $163.
  • Harbour Investments first reported a position in Quince Therapeutics in Q2 2025 and held it in 2 quarters.
  • Harbour Investments's Quince Therapeutics position peaked at $165 in Q2 2025.
  • 62 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2025.

Based on Harbour Investments's 13F filing for Q4 2025, filed 9 Feb 2026.